CytomX Therapeutics Inc . (NASDAQ:CTMX) stock has reached a new 52-week low, trading at $0.76, as the biopharmaceutical company faces a challenging market environment. Despite the recent decline, ...

Minerva Neurosciences Inc. (NASDAQ:NERV) stock has reached a new 52-week low, trading at $2.02, signaling a period of significant bearish sentiment among investors. According to InvestingPro data, the ...

HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

IRA has unintended consequences on investment landscape for small- and large-molecule drugs stifling the development of new ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their ...

U.S. Rep. April McClain Delaney visited Kite, a biopharmaceutical company that uses cell therapy to treat cancer, in Urbana ...

Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...

LIB Therapeutics Inc. (LIB), a privately-held, late-stage biopharmaceutical company today announced the U.S. Food and Drug Administration (FDA) has ac ...

LB Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of ...